CORRESP Filing
Edesa Biotech, Inc.
Date: Sept. 5, 2025 · CIK: 0001540159 · Accession: 0001171843-25-005749
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-288966
Letter
Edesa Biotech, Inc.
100 Spy Court
Markham, Ontario, Canada L3R 5H6
September 5, 2025
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Re: Edesa Biotech, Inc.
Registration Statement on Form S-3 (File No. 333-288966)
Filed on July 25, 2025
Ladies and Gentlemen:
In accordance with Rule 461 under the Securities Act of 1933, as amended, Edesa Biotech, Inc. (the " Company ") hereby requests that the above-referenced Registration Statement (the " Registration Statement ") be declared effective by the Securities and Exchange Commission at 4:00 p.m., Eastern Time, on September 9, 2025, or as soon as practicable thereafter.
Please call Tracy Buffer of Lowenstein Sandler LLP at (973) 597-2434 to confirm the effectiveness of the Registration Statement or with any questions.
Very truly yours,
EDESA BIOTECH, INC.
Show Raw Text
CORRESP 1 filename1.htm Edesa Biotech, Inc. 100 Spy Court Markham, Ontario, Canada L3R 5H6 September 5, 2025 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Edesa Biotech, Inc. Registration Statement on Form S-3 (File No. 333-288966) Filed on July 25, 2025 Ladies and Gentlemen: In accordance with Rule 461 under the Securities Act of 1933, as amended, Edesa Biotech, Inc. (the " Company ") hereby requests that the above-referenced Registration Statement (the " Registration Statement ") be declared effective by the Securities and Exchange Commission at 4:00 p.m., Eastern Time, on September 9, 2025, or as soon as practicable thereafter. Please call Tracy Buffer of Lowenstein Sandler LLP at (973) 597-2434 to confirm the effectiveness of the Registration Statement or with any questions. Very truly yours, EDESA BIOTECH, INC. By: /s/ Peter Weiler Name: Peter Weiler Title: Chief Financial Officer